Gemcitabine Plus FOLFIRI May Be Safe and Effective as First-Line Treatment of Metastatic Pancreatic Cancer
the Cancer Therapy Advisor take:
According to a new study published in the European Journal of Cancer, researchers have found that a sequential approach of alternating irinotecan, leucovorin, fluorouracil, and gemcitabine may be a safe and effective strategy for the treatment of patients with metastatic pancreatic adenocarcinoma.
For the phase 2 study, researchers sought to investigate fixed-dose rate gemcitabine alone or alternating with irinotecan, leucovorin, and fluorouracil as first-line treatment for patients with metastatic pancreatic cancer. Researchers enrolled 98 patients between October 2007 and March 2011.
Participants were randomly assigned 1:1 to receive fixed-dose rate gemcitabine alone or irinotecan, leucovorin, and fluorouracil alternating with fixed-dose rate gemcitabine as 2-month periods. All patients had a World Health Organization performance status of 0 or 1 and bilirubin levels <1.5 the upper limit of normal.
At 6 months, researchers observed a progression-free survival rate of 43.5% (95% CI, 28.6 - 58.4) in the alternating regimen group and 26.1% (95% CI, 12.9 - 39.3) in the gemcitabine alone group. The findings suggest that this alternating strategy may be a safe and effective approach to first-line treatment of patients with metastatic pancreatic adenocarcinoma.
Alternating irinotecan, leucovorin, fluorouracil, and gemcitabine may be a safe and effective.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers
- The Price Is Right for CAR-T in Pediatric Patients, Analysis Concludes
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection